Mira Pharmaceuticals (MIRA) Gains from Investment Securities (2022 - 2025)
Mira Pharmaceuticals (MIRA) posted Gains from Investment Securities of $100000.0 for Q4 2025, up 33.33% sequentially from $75000.0 in Q3 2025, and down 97.64% YoY from $4.2 million in Q4 2024.
Mira Pharmaceuticals (MIRA) Gains from Investment Securities (2022 - 2025) Analysis & Trends
Mira Pharmaceuticals (MIRA) has 4 years of Gains from Investment Securities data on file, last reported at $100000.0 in Q4 2025.
- Quarterly Gains from Investment Securities fell 97.64% year-over-year to $100000.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $100000.0 (down 97.64% YoY) and the FY2025 annual result came in at $100000.0, down 97.64% from the prior year.
- Gains from Investment Securities rose to $100000.0 in Q4 2025 per MIRA's latest filing, from $75000.0 in the prior quarter.
- The five-year high for Gains from Investment Securities was $4.2 million in Q4 2024, with the low at $33332.0 in Q1 2025.
- Average Gains from Investment Securities over 4 years is $1.2 million, with a median of $680000.5 recorded in 2023.
- The widest YoY moves for Gains from Investment Securities: up 884.92% in 2025, down 97.64% in 2025.
- Mira Pharmaceuticals' Gains from Investment Securities stood at $750000.0 in 2022, then jumped by 62.0% to $1.2 million in 2023, then jumped by 248.61% to $4.2 million in 2024, then sank by 97.64% to $100000.0 in 2025.
- Business Quant data shows MIRA's Gains from Investment Securities at $100000.0 in Q4 2025, $75000.0 in Q3 2025, and $4.2 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Eli Lilly | 1,066.16 Bn | 1,060.88 Bn | 16.22 Bn |
| 2 | Johnson & Johnson | 611.69 Bn | 589.64 Bn | 15.96 Bn |
| 3 | AbbVie | 444.34 Bn | 434.99 Bn | 10.78 Bn |
| 4 | Astrazeneca | 284.94 Bn | 277.05 Bn | 12.61 Bn |
| 5 | Merck | 224.23 Bn | 218.58 Bn | 12.09 Bn |
| 6 | Amgen | 195.12 Bn | 183.08 Bn | 5.87 Bn |
| 7 | Gilead Sciences | 156.45 Bn | 148.73 Bn | 5.52 Bn |
| 8 | Pfizer | 136.01 Bn | 123.24 Bn | -1.21 Bn |
| 9 | Novartis Ag | 113.45 Bn | 113.67 Bn | - |
| 10 | Mira Pharmaceuticals | 22.51 Mn | 11.48 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 100,000.00 |
| Dec 31, 2025 | 100,000.00 |
| Sep 30, 2025 | 75,000.00 |
| Sep 30, 2025 | 75,000.00 |
| Jun 30, 2025 | 4.20 Mn |
| Jun 30, 2025 | 4.20 Mn |
| Mar 31, 2025 | 33,332.00 |
| Mar 31, 2025 | 33,332.00 |
| Dec 31, 2024 | 4.24 Mn |
| Dec 31, 2024 | 4.24 Mn |
| Sep 30, 2024 | 546,667.00 |
| Sep 30, 2024 | 546,667.00 |
| Jun 30, 2024 | 426,667.00 |
| Jun 30, 2024 | 426,667.00 |
| Mar 31, 2024 | 725,000.00 |
| Mar 31, 2024 | 725,000.00 |
| Dec 31, 2023 | 1.22 Mn |
| Dec 31, 2023 | 1.22 Mn |
| Sep 30, 2023 | 635,001.00 |
| Sep 30, 2023 | 635,001.00 |